Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Lack of consensus for first‐line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Becnel, Melody R., Nastoupil, Loretta J., Samaniego, Felipe, Davis, Richard E., You, M. J., Green, Michael, Hagemeister, Fredrick B., Fanale, Michelle A., Fayad, Luis E., Westin, Jason R., Wang, Michael, Oki, Yasuhiro, Forbes, Sheryl G., Feng, Lei, Neelapu, Sattva S., Fowler, Nathan H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6619290/
https://ncbi.nlm.nih.gov/pubmed/30919940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15843
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados